Modulation of hepcidin to treat iron deregulation: Potential clinical applications

Expert Review of Hematology

Volumn 9, Issue 2, 2016, Pages 169-186

  Blanchette, Nicole L ^a   Manz, David H ^a   Torti, Frank M ^a   Torti, Suzy V ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

anemia of chronic disease; clinical trials; ferroportin; Hepcidin; iron deficiency; iron overload

Indexed keywords

6 [4 (1 PIPERAZINYL)PHENYL] 3 (4 QUINOLINYL)PYRAZOLO[1,5 A]PYRIMIDINE; CURCUMIN; DORSOMORPHIN; HEPARIN; HEPCIDIN; INFLIXIMAB; INTERLEUKIN 6; IRON; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SILTUXIMAB; TOCILIZUMAB; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR; CATION TRANSPORT PROTEIN; FAM132B PROTEIN, HUMAN; METAL TRANSPORTING PROTEIN 1; PEPTIDE HORMONE;

ANEMIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; IRON METABOLISM DISORDERS; METABOLISM; SIGNAL TRANSDUCTION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; CATION TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HEPCIDINS; HOMEOSTASIS; HUMANS; INTERLEUKIN-6; IRON; IRON METABOLISM DISORDERS; PEPTIDE HORMONES; SIGNAL TRANSDUCTION;

EID: 84957842438     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2016.1124757     Document Type: Review

References (159)

1. Crichton RR. Iron metabolism: from molecular mechanisms to clinical consequences. Chichester (UK): John Wiley & Sons; 2009.
2. Dizdaroglu M, Rao G, Halliwell B, et al. Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch Biochem Biophys. 1991; 285 (2): 317-324.
3. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000; 403 (6771): 776-781.
4. Schade AL, Reinhart RW, Levy H. Carbon dioxide and oxygen in complex formation with iron and siderophilin, the iron-binding component of human plasma. Arch Biochem. 1949; 20 (1): 170-172.
5. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 2000; 480 (2-3): 147-150.
6. Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276 (11): 7806-7810.
7. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001; 276 (11): 7811-7819.
8. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA. 2001; 98 (15): 8780-8785.
9. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis. 2008; 40 (1): 132-138.
10. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306 (5704): 2090-2093.
11. Preza GC, Pinon R, Ganz T, et al. Cellular catabolism of the iron-regulatory peptide hormone hepcidin. Plos One. 2013; 8 (3): e58934.
12. Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 2005; 1 (3): 191-200.
13. Pinnix ZK, Miller LD, Wang W, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010; 2 (43): 43ra56.
14. Tesfay L, Clausen KA, Kim JW, et al. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 2015; 75 (11): 2254-2263.
15. Raha AA, Vaishnav RA, Friedland RP, et al. The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimers disease. Acta Neuropathol Commun. 2013; 1: 55.
16. Olynyk JK, Trinder D, Ramm GA, et al. Hereditary hemochromatosis in the post-HFE era. Hepatology. 2008; 48 (3): 991-1001.
17. Sham RL, Phatak PD, West C, et al. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis. 2005; 34 (2): 157-161.
18. Piperno A, Girelli D, Nemeth E, et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood. 2007; 110 (12): 4096-4100.
19. Pippard MJ, Callender ST, Warner GT, et al. Iron absorption and loading in beta-thalassaemia intermedia. Lancet. 1979; 2 (8147): 819-821.
20. Iolascon A, Esposito MR, Russo R. Clinical aspects and pathogenesis of congenital dyserythropoietic anemias: from morphology to molecular approach. Haematologica. 2012; 97 (12): 1786-1794.
21. Pootrakul P, Sirankapracha P, Hemsorach S, et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood. 2000; 96 (7): 2606-2612.
22. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007; 13 (9): 1096-1101.
23. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46 (7): 678-684.
24. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007; 92 (5): 583-588.
25. Roy CN. Anemia of inflammation. Hematol Am Soc Hematol Educ Program. 2010; 2010: 276-280.
26. Chung A, Leo K, Wong G, et al. Giant hepatocellular adenoma presenting with chronic iron deficiency anemia. Am J Gastroenterol. 2006; 101 (9): 2160-2162.
27. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008; 40 (5): 569-571.
28. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113 (9): 1271-1276.
29. Ward DG, Roberts K, Stonelake P, et al. SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Sci. 2008; 6: 28.
30. Laarakkers CM, Wiegerinck ET, Klaver S, et al. Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. Plos One. 2013; 8 (10): e75518.
31. Kobold U, Dulffer T, Dangl M, et al. Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry. Clin Chem. 2008; 54 (9): 1584-1586.
32. Murao N, Ishigai M, Yasuno H, et al. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007; 21 (24): 4033-4038.
33. Wolff F, Deleers M, Melot C, et al. Hepcidin-25: measurement by LC-MS/MS in serum and urine, reference ranges and urinary fractional excretion. Clin Chim Acta. 2013; 423: 99-104.
34. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood. 2008; 112 (10): 4292-4297.
35. Delaby C, Vialaret J, Bros P, et al. Clinical measurement of Hepcidin-25 in human serum: is quantitative mass spectrometry up to the job? EuPA Open Proteomics. 2014; 3: 60-67.
36. Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006; 108 (4): 1381-1387.
37. Kroot JJ, Van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol. 2012; 87 (10): 977-983.
38. Xiao JJ, Krzyzanski W, Wang YM, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. Aaps J. 2010; 12 (4): 646-657.
39. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823 (9): 1434-1443.
40. Chen D, Zhao M, Harris SE, et al. Signal transduction and biological functions of bone morphogenetic proteins. Front Biosci. 2004; 9: 349-358.
41. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010; 147 (1): 35-51.
42. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005; 2 (6): 399-409.
43. Andriopoulos B Jr., Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41 (4): 482-487.
44. Meynard D, Kautz L, Darnaud V, et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009; 41 (4): 478-481.
45. Xia Y, Babitt JL, Sidis Y, et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood. 2008; 111 (10): 5195-5204.
46. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006; 38 (5): 531-539.
47. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003; 33 (1): 21-22.
48. Lee PL, Beutler E, Rao SV, et al. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood. 2004; 103 (12): 4669-4671.
49. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13 (4): 399-408.
50. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000; 25 (1): 14-15.
51. Goswami T, Andrews NC. Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem. 2006; 281 (39): 28494-28498.
52. Ganz T. The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. Isr Med Assoc J. 2002; 4 (11): 1043-1045.
53. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101 (7): 2461-2463.
54. Verga Falzacappa MV, Vujic Spasic M, Kessler R, et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007; 109 (1): 353-358.
55. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006; 8 (Suppl 2): S3.
56. Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117 (7): 1933-1939.
57. Peterson PW. Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors. Cancer Res. 2015; 75 (15 Supplement):3647.
58. Theurl I, Schroll A, Sonnweber T, et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011; 118 (18): 4977-4984.
59. Poli M, Girelli D, Campostrini N, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood. 2011; 117 (3): 997-1004.
60. Mayeur C, Lohmeyer LK, Leyton P, et al. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood. 2014; 123 (14): 2261-2268.
61. Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood. 2008; 111 (12): 5727-5733.
62. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010; 95 (3): 505-508.
63. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol. 2010; 299 (1): F1-F13.
64. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007; 117 (7): 1926-1932.
65. Mastrogiannaki M, Matak P, Keith B, et al. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest. 2009; 119 (5): 1159-1166.
66. Volke M, Gale DP, Maegdefrau U, et al. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. Plos One. 2009; 4 (11): e7875.
67. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008; 111 (2): 924-931.
68. Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8 (6): 502-511.
69. Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005; 106 (8): 2884-2889.
70. Yanagita M, Oka M, Watabe T, et al. USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney. Biochem Biophys Res Commun. 2004; 316 (2): 490-500.
71. Yang Q, Jian J, Katz S, et al. 17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology. 2012; 153 (7): 3170-3178.
72. Ikeda Y, Tajima S, Izawa-Ishizawa Y, et al. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. Plos One. 2012; 7 (7): e40465.
73. Guo W, Bachman E, Li M, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013; 12 (2): 280-291.
74. Mei S, Wang H, Fu R, et al. Hepcidin and GDF15 in anemia of multiple myeloma. Int J Hematol. 2014; 100 (3): 266-273.
75. Jiang F, Yu WJ, Wang XH, et al. Regulation of hepcidin through GDF-15 in cancer-related anemia. Clin Chim Acta. 2014; 428: 14-19.
76. Goodnough JB, Ramos E, Nemeth E, et al. Inhibition of hepcidin transcription by growth factors. Hepatology. 2012; 56 (1): 291-299.
77. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280 (20): 19883-19887.
78. Mleczko-Sanecka K, Roche F, da Silva AR, et al. Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. Blood. 2014; 123 (10): 1574-1585.
79. Preza GC, Ruchala P, Pinon R, et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest. 2011; 121 (12): 4880-4888.
80. Ramos E, Ruchala P, Goodnough JB, et al. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood. 2012; 120 (18): 3829-3836.
81. Merganser biotech. Development compound: M012 [Internet]. 2015 [cited 2015 Sep 10]. Available from: http://merganserbiotech.com/hepcidin-mimetic-peptides/development-compound-m012/
82. La Jolla Pharmaceutical Company. LJPC-401 [Internet]. 2015 [cited 2015 Sep 10]. Available from: http://lajollapharmaceutical.com/product-pipeline/ljpc-401/
83. La Jolla Pharmaceutical Company. Corportate presentation: developing innovative therapies for patients suffering from life-threatening diseases [Internet]. 2015 [cited 2015 Sep 10]. Available from: http://lajollapharmaceutical.com/wp-content/uploads/2015/09/Sept-2015-Corporate-Presentation-9-17-2015-vJL.pdf
84. Corradini E, Schmidt PJ, Meynard D, et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology. 2010; 139 (5): 1721-1729.
85. Butler J, Fishman S, Racie T, et al. Aln-TMP.: a subcutaneously administered RNAi therapeutic targeting TMPRSS6 for the treatment of β-thalassemia. Blood. 2013;122(21):2260.
86. Casu B, Diamantini G, Fedeli G, et al. Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. Arzneimittelforschung. 1986; 36 (4): 637-642.
87. Poli M, Asperti M, Naggi A, et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood. 2014; 123 (10): 1564-1573.
88. Ritchie JP, Ramani VC, Ren Y, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res. 2011; 17 (6): 1382-1393.
89. Sigma Tau Research Switzerland SA. Phase I dose finding study assessing safety and tolerability of SST0001 in advanced multiple myeloma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [. cited 2015 Sep 10[. Available from: https://clinicaltrials.gov/ct2/show/NCT01764880: NCT01764880
90. Naggi A, Casu B, Perez M, et al. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem. 2005; 280 (13): 12103-12113.
91. FerruMax Pharmaceuticals I. An exploratory, uncontrolled, open-labeled trial to evaluate the effect of FMX-8 treatment for anemia in patients with chronic kidney disease (CKD), stage 4 or 5. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [ cited 2015 Sep 10[. Available from: https://clinicaltrials.gov/ct2/show/NCT02228655: NCT02228655
92. FerruMax Pharmaceuticals I. A phase 2A, uncontrolled, open-labeled trial to evaluate the effect of FMX-8 treatment for anemia in patients with end stage renal disease (ESRD) on hemodialysis (HD). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015. Sep 10[. Available from: https://clinicaltrials.gov/ct2/show/NCT01873534: NCT01873534
93. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008; 4 (1): 33-41.
94. Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008; 14 (12): 1363-1369.
95. Steinbicker AU, Sachidanandan C, Vonner AJ, et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood. 2011; 117 (18): 4915-4923.
96. La Jolla Pharmaceutical Company. La Jolla pharmaceutical company announces second-quarter 2013 financial results and highlights recent corporate progress [Internet]. 2013 [cited 2015 Sep 10]. Available from: http://www.sec.gov/Archives/edgar/data/920465/000119312513301480/d573357dex991.htm
97. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal. 2011; 23 (11): 1831-1842.
98. Tolero Pharmaceuticals, Inc. Tolero pharmaceuticals presents positive preclinical data on hepcidin inhibition for the treatment of anemia associated with chronic disease [Internet]. 2015 [cited 2015 Sep 10]. Available from: http://www.businesswire.com/news/home/20150616006060/en/Tolero-Pharmaceuticals-Presents-Positive-Preclinical-Data-Hepcidin#.VgLnb8tVikp
99. Boser P, Seemann D, Liguori MJ, et al. Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation. Aaps J. 2015; 17 (4): 930-938.
100. Xenon Pharmaceuticals Inc. Xenon licenses antisense drug XEN701 from Isis and initiates preclinical toxicology studies; 2013 [cited 2015 Sep 10]. Available from: http://www.xenon-pharma.com/2013/06/isis/
101. Xenon Pharmaceuticals, Inc. FORM S-1 [Internet]. 2014 [cited 2015 Sep 10]. Available from: http://www.sec.gov/Archives/edgar/data/1582313/000119312514337038/d582812ds1.htm
102. Akinc A, Chan-Daniels A, Sehgal A, et al. Targeting the hepcidin pathway with RNAi therapeutics for the treatment of anemia [abstract]. In: ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington (DC): ASH; 2011. Abstract nr 688.
103. Casper C, Chaturvedi S, Munshi N, et al. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric castleman disease. Clin Cancer Res. 2015 Oct 1;21(19):4294-4304.
104. Angevin E, Tabernero J, Elez E, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014; 20 (8): 2192-2204.
105. Schipperus M, Rijnbeek B, Reddy M, et al. CNTO328 (anti-IL-6 mAb) treatment is associated with an increase in hemoglobin (Hb) and decrease in hepcidin levels in renal cell carcinoma (RCC). Blood. 2009;114(22):4045.
106. Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010; 116 (18): 3627-3634.
107. Song SN, Iwahashi M, Tomosugi N, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013; 15 (5): R141.
108. Isaacs JD, Harari O, Kobold U, et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013; 15 (6): R204.
109. De Vos J, Jourdan M, Tarte K, et al. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000; 109 (4): 823-828.
110. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004; 3 (3): 261-269.
111. Fatih N, Camberlein E, Island ML, et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010; 88 (5): 477-486.
112. Zhang SP, Wang Z, Wang LX, et al. AG490: an inhibitor of hepcidin expression in vivo. World J Gastroenterol. 2011; 17 (45): 5032-5034.
113. Jiao Y, Wilkinson J 4th, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009; 113 (2): 462-469.
114. Chin D, Huebbe P, Frank J, et al. Curcumin may impair iron status when fed to mice for six months. Redox Biol. 2014; 2: 563-569.
115. Badria FA, Ibrahim AS, Badria AF, et al. Curcumin attenuates iron accumulation and oxidative stress in the liver and spleen of chronic iron-overloaded rats. PLoS One. 2015; 10 (7): e0134156.
116. Kandala PK, Srivastava SK. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo. Drug Discov Ther. 2012; 6 (2): 94-101.
117. Tilton SC, Hendricks JD, Orner GA, et al. Gene expression analysis during tumor enhancement by the dietary phytochemical, 3,3-diindolylmethane, in rainbow trout. Carcinogenesis. 2007; 28 (7): 1589-1598.
118. Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014; 124 (16): 2569-2574.
119. Avalon Ventures. Avalon ventures and GlaxoSmithKline launch two new companies with $10 million each in series A financing and R&D support [Internet]. 2014 [cited 2015 Sep 10]. Available from: http://www.prnewswire.com/news-releases/avalon-ventures-and-glaxosmithkline-launch-two-new-companies-with-10-million-each-in-series-a-financing-and-rd-support-275982981.html
120. Kautz L. Erythroferrone, an erythroid regulator of iron metabolism. Med Sci (Paris). 2014; 30 (10): 834-836.
121. Cooke KS, Hinkle B, Salimi-Moosavi H, et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood. 2013; 122 (17): 3054-3061.
122. Hohlbaum AM, Trentman S, Gille H, et al. Discovery and preclinical characterization of a novel hepcidin antagonist with tunable PK/PD properties for the treatment of anemia in different patient populations [abstract]. In: ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, CA. Washington (DC): ASH; 2011. Abstract nr 687.
123. Mross K, Richly H, Fischer R, et al. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One. 2013; 8 (12): e83232.
124. Pieris AG. A first-in-human, randomized, dose-escalation, double-blind, placebo-controlled single ascending dose study to establish safety, lack of immunogenicity, tolerability, pharmacokinetic parameters, target engagement and pharmacodynamic effects. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [. cited 2015 Sep 10[. Available from: https://clinicaltrials.gov/ct2/show/NCT02340572: NCT02340572
125. Schwoebel F, Van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013; 121 (12): 2311-2315.
126. Riecke K, Zollner S, Boyce M., et al. Single and repeated dose first-in-human study with the anti-hepcidin spiegelmer Nox-H94 [abstract]. In: ASH Annual Meeting and Exposition; 2012 Dec 8-12; Atlanta,GA. Washington (DC): ASH; 2012. Abstract nr 2342.
127. Van Eijk L, Swinkels DW, John A, et al. Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human endotoxemia. Crit Care. 2013; 17 (2): 1-200.
128. Georgiev P, Lazaroiu M, Ocroteala L, et al. The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: a phase II pilot study. Cancer Res. 2014; 74 (19 Supplement): 3847.
129. NOXXON Pharma AG. Safety, PK/PD, and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anemia: a randomized, double blind, placebo controlled parallel group study with a single blind cross-over group. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [. cited 2015 Sep 10[. Available from. https://www.clinicaltrials.gov/ct2/show/NCT02079896: NCT02079896
130. Eli Lilly and Company. A Phase 1 safety study of LY2787106 in patients with cancer and anemia. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [. cited 2015 Sep 10[. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01340976: NCT01340976)
131. Eli Lilly and Company. Q4 2014 financial review [Internet]. 2015. Available from: http://files.shareholder.com/downloads/LLY/0x0x806041/8456ABB4-DE7C-4193-95EA-64400D334C44/Q4-2014-Slides.pdf
132. Leung D, Hill KA, De Rosa DC., et al. LY2928057, an antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys. Blood. 2013; 122 (21): 3433.
133. Eli Lilly and Company. A multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LY2928057 in hemodialysis patients. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [. cited. 2015 Sep 10[. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01991483: NCT01991483
134. Fung E, Sugianto P, Hsu J, et al. High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol. 2013; 83 (3): 681-690.
135. Gagliardo B, Faye A, Jaouen M, et al. Production of biologically active forms of recombinant hepcidin, the iron-regulatory hormone. Febs J. 2008; 275 (15): 3793-3803.
136. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011; 11 (6): 471-491.
137. Nai A, Pagani A, Mandelli G, et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia. Blood. 2012; 119 (21): 5021-5029.
138. Guo S, Casu C, Gardenghi S, et al. Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice. J Clin Invest. 2013; 123 (4): 1531-1541.
139. Schmidt PJ, Toudjarska I, Sendamarai AK, et al. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood. 2013; 121 (7): 1200-1208.
140. Schmidt PJ, Racie T, Westerman M, et al. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-thalassemia intermedia. Am J Hematol. 2015; 90 (4): 310-313.
141. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988; 242 (4885): 1528-1534.
142. Rider CC. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans. 2006; 34 (Pt 3): 458-460.
143. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012; 226 (2): 365-379.
144. Wittrup A, Lieberman J. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015; 16 (9): 543-552.
145. Nair JK, Willoughby JL, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014; 136 (49): 16958-16961.
146. Sorensen B, Mant T, Akinc A, et al. A subcutaneously administered RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim Phase 1 study results in healthy volunteers and patients with hemophilia A or B. Blood. 2014; 124 (21): 693.
147. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013; 19 (13): 3659-3670.
148. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 2003; 171 (7): 3863-3871.
149. McMurray JS, Mandal PK, Liao WS, et al. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain. Jakstat. 2012; 1 (4): 263-347.
150. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013; 12 (8): 611-629.
151. Lavecchia A, Di Giovanni C, Cerchia C. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature. Expert Opin Ther Pat. 2014; 24 (4): 383-400.
152. Sonbol MB, Firwana B, Zarzour A, et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol. 2013; 4 (1): 15-35.
153. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91 (19): 1616-1634.
154. Gebauer M, Skerra A. Anticalins small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol. 2012; 503: 157-188.
155. Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer((R)) therapeutics. Drug Discov Today. 2015; 20 (1): 147-155.
156. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010; 115 (17): 3616-3624.
157. Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst. 1985; 75 (1): 81-84.
158. Zhang S, Chen Y, Guo W, et al. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell Signal. 2014; 26 (11): 2539-2550.
159. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013; 13 (5): 342-355.